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Mutations affecting the conversion of PI3P to the signaling lipid PI(3,5)P2 result in spongiform degeneration
of mouse brain and are associated with the human disorders Charcot–Marie–Tooth disease and amyotrophic
lateral sclerosis (ALS). We now report accumulation of the proteins LC3-II, p62 and LAMP-2 in neurons and
astrocytes of mice with mutations in two components of the PI(3,5)P2 regulatory complex, Fig4 and Vac14.
Cytoplasmic inclusion bodies containing p62 and ubiquinated proteins are present in regions of the
mutant brain that undergo degeneration. Co-localization of p62 and LAMP-2 in affected cells indicates that
formation or recycling of the autolysosome is impaired. These results establish a role for PI(3,5)P2 in autop-
hagy in the mammalian central nervous system (CNS) and demonstrate that mutations affecting PI(3,5)P2 can
contribute to inclusion body disease.
INTRODUCTION
The phosphatidylinositide PI(3,5)P2 is a low-abundance signal-
ing lipid that is synthesized on the cytoplasmic surface of
vesicular organelles in eukaryotic cells from yeast to
mammals. PI(3,5)P2 synthesis and degradation are regulated
by a protein complex that includes the PI3P kinase FAB1
(also known as PIP5K3 and PIKfyve), the Pl(3,5)P2 5-
phosphatase FIG4 and the scaffold protein VAC14 (1,2). We
have described recessive mutations of human FIG4 (also
known as SAC3) in the peripheral nerve disorder Charcot–
Marie–Tooth Type 4J (OMIM 611228) (3), and heterozygous
deleterious mutations of FIG4 in 1% of patients with amyo-
trophic lateral sclerosis (ALS) (4). In mouse models, mutations
of Fig4 and Vac14 result in a 50–75% reduction in the levels
of PI(3,5)P2 in cultured ﬁbroblasts and progressive neurode-
generation that begins in fetal life and results in lethality
between birth and 6 weeks of age (2,3,5). Affected mice
exhibit extensive spongiform degeneration of the central
nervous system (CNS) and substantial loss of peripheral
neurons from sensory and sympathetic ganglia.
The PI(3,5)P2 regulatory complex is located on the vacuolar
membrane in yeast, where synthesis and degradation of
Pl(3,5)P2 are tightly coupled (2). In yeast, mutations in this
regulatory complex result in reduction of PI(3,5)P2 and enlar-
gement of the vacuole. Mammalian cells do not contain a
precise counterpart to the yeast vacuole. Mammalian FAB1
and FIG4 are associated with intracellular vesicles of the
early and late endosome (6–8). In mice carrying spontaneous
mutations of Fig4 (pale tremor) and Vac14 (ingls), the cellular
concentration of PI(3,5)P2 is reduced and there is accumu-
lation of swollen intracellular vacuoles that appear empty of
stored material in neurons and in cultured ﬁbroblasts (2,3).
Similarly, cultured ﬁbroblasts from CMT4J patients who are
deﬁcient in FIG4 exhibit extensive cytoplasmic vacuolization
(9). Treatment of mammalian cells with siRNAs to reduce
expression of Fig4 and FAB1 also results in swollen intracellu-
lar vacuoles (10). The membrane of the enlarged vesicles in
cultured ﬁbroblasts from Fig4 null mice stains strongly for
LAMP-2, a marker of late endosomes and lysosomes (3).
These previous studies have implicated PI(3,5)P2 in the regu-
lation of intracellular trafﬁcking in yeast and mammalian cells.
Current models suggest that PI(3,5)P2 is synthesized on
endosomes and lysosomes in response to speciﬁc cargo mol-
ecules (10). Membrane-bound PI(3,5)P2 is thought to interact
with membrane proteins, and to recruit cytosolic effector pro-
teins required for trafﬁcking cargo. Through these interactions,
synthesis of PI(3,5)P2 directs trafﬁcking of cargo vesicles
along the endosome–lysosome axis and promotes recycling
of membranes to the trans-Golgi network (7).
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Advance Access published on September 29, 2009Macroautophagy (autophagy) is a ubiquitous eukaryotic
pathway for degrading damaged organelles and long-lived
intracellular proteins (11). Autophagy provides nutrients
during periods of starvation and serves as a quality control
mechanism for misfolded proteins. During autophagy,
ubiquitin-tagged substrates are sequestered within double-
membrane vesicles that are thought to be enriched in PI3P,
the precursor of PI(3,5)P2 (12). Completed autophagosomes
can fuse directly with lysosomes, or with endosomal vesicles
prior to lysosome fusion, in order to deliver substrates for
degradation. In yeast, reduction of PI(3,5)P2 does not appear
to affect autophagy (10). In mammalian cells, autophagy is
dependent on maturation of early endosomes (13). In view
of the established role of PI(3,5)P2 in endosomal trafﬁcking,
we hypothesized that reduced levels of PI(3,5)P2 might
affect the progression of autophagy in mammalian cells, and
that the resulting impairment of autophagy could be respon-
sible for the extensive neurodegeneration in the PI(3,5)P2-
deﬁcient mutants Fig4 (pale tremor) and Vac14 (ingls).
The work described here directly tests the hypothesis that
there is a block in autophagy in Fig4 and Vac14 mutant
mice. Our data support and extend the evidence that
PI(3,5)P2 is an essential component of the autophagy
pathway. We demonstrate that impaired autophagy underlies
neurodegeneration in these mutant mice and is likely to con-
tribute to related human disorders.
RESULTS
Autophagy markers in Fig4
2/2 brain
p62/SQSTM1 binds polyubiquinated protein substrates des-
tined for autophagic degradation. Using western blotting, we
assessed the amount of p62 in Fig4
2/2 null mice. A signiﬁ-
cant increase in abundance of p62 was observed in brain and
spinal cord (Fig. 1A). The abundance of p62 in 10 mgo f
mutant brain is comparable with that in 30 mg of wild-type
brain, indicating that p62 is increased 3-fold in the mutant
(Fig. 1A). Analysis of brain RNA by qRT-PCR demonstrated
that the level of p62 transcript is not elevated (Fig. 1B). p62
accumulation is limited to brain and spinal cord, and was
not observed in liver or other non-neural tissues (Fig. 1C).
LC3-II (MAP1LC3), a component of the autophagosome
membrane that binds p62, is generated by conjugation of phos-
phatidylethanolamine to the cytosolic protein LC3-I, resulting
in faster electrophoretic mobility. Elevated LC3-II, but not
LC3-I, is a consequence of defective autophagosome clear-
ance (14). Examination of brain homogenates by western blot-
ting demonstrated an increase in the level of LC3-II in the
Fig4
2/2 mutant (Fig. 1D). There is no change in cytoplasmic
LC3-I (Fig. 1E). The increased levels of p62 and LC3-II
indicate that the process of autophagy is altered in PI(3,5)P2-
deﬁcient Fig4
2/2 mice.
Autophagy is not up-regulated in mutant brain
The accumulation of LC3-II could result either from an elev-
ated rate of basal autophagy, as observed in some lysosomal
storage disorders, or from a block in the completion of
autophagy. To distinguish between these, we examined the
abundance of several proteins involved in the initiation of
autophagy. Beclin-1 is a subunit of the class III PI3-kinase
complex that is required for autophagosome formation.
In Fig4
2/2 brain, the level of beclin-1 protein was comparable
to that of wild type (Fig. 2A). Mammalian target of rapamycin
(mTOR) is an important regulator of autophagy that is elev-
ated in some lysosomal storage disorders. In mutant brain,
we observed normal levels of Ser2448-phosphorylated and
total mTOR (Fig. 2B and C). We also examined phosphory-
lated p70 S6 kinase (p-S6K), an intermediate in regulation
by mTOR. The level of p-S6K was normal in the mutant
brain (Fig. 2D). These data indicate that the accumulation of
autophagy intermediates in Fig4
2/2 brain is likely to result
from a block in completion of basal autophagy rather than
up-regulation of the pathway.
p62 and ubiquitin in inclusion bodies
Insoluble protein aggregates containing p62 and ubiquitin are
a common feature of several types of neurodegenerative
disease (15). To determine whether the elevated p62 in
Fig4
2/2 brain is associated with ubiquitinated protein, brain
slices were immunostained for p62 and ubiquitin.
Co-localization of p62 and ubiquitin was evident in sections
of the cortex (Fig. 3A) and other regions of the brain. Both
Figure 1. Markers of autophagy are elevated in brain from Fig4
2/2 brain.
Total brain homogenates were examined by western blotting with antibodies
to components of the autophagy pathway. (A) Accumulation of p62 in
mutant brain and spinal cord (left and middle panels); quantitative comparison
(right panel). (B) qRT-PCR analysis of p62 transcript, relative to the Tata-
binding protein transcript, in total brain RNA. Mean+SD (n ¼ 3 mice of
each genotype, assayed in quadruplicate). (C) Normal levels of p62 protein
in non-neural tissues. (D) Elevation of LC3-II in mutant brain. (E) Normal
level of LC3-I in mutant brain [short exposure of the ﬁlm in (D)]. (A)–(C)
30 mg protein per lane; (D)–(E) 50 mg protein per lane.
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intracellular inclusions that sometimes extended into cell
processes (Fig. 3B and C). Ultrastructural analysis of the
brainstem revealed numerous electron-dense cytoplasmic
vesicles that range in diameter from 0.25 to 4 mm (Fig. 3D)
and resemble those in other neurodegenerative disorders
(15). Consistent with localization of p62 in inclusion bodies,
a signiﬁcant proportion of p62 is pelleted by centrifugation
of mutant brain homogenates at 15 000g (Fig. 3E).
Inclusion bodies do not contain TDP-43
In some forms of ALS, the nuclear DNA-binding protein
TDP-43 is co-localized in cytoplasmic inclusion bodies that
contain p62 and ubiquitin (16–18). We did not detect any
increase in TDP-43 protein in Fig4
2/2 brain by western blot
(Supplementary Material, Fig. S1A). Immunostaining revealed
normal nuclear localization of TDP-43 (Supplemental
Material, Fig. S1B), and lack of co-localization with
Figure 2. Normal levels of proteins involved in initiation and mTOR-mediated regulation of autophagy. (A) beclin-1; (B) mTOR; (C) Ser2448 phospho-mTOR;
(D) phosphorylated p70 S6 kinase, a downstream target of mTORC1. Thirty micrograms of protein per lane.
Figure 3. p62 is co-localized with ubiquitin in intracellular inclusion bodies. (A) Two-color immunoﬂuorescence of cortical sections from Fig4
2/2 mouse
demonstrates co-localization of ubiquitin and p62. (B and C) Peroxidase immunostaining detects immunodense cytoplasmic inclusion bodies containing p62
and ubiquitin in mutant brain that are not present in wild-type controls. (D) Ultrastructure (TEM) of Fig4
2/2 brainstem at 7 days of age. (E) Western blot
of soluble protein and 15 000g pellet from brain homogenates prepared in radioimmunoprecipitation buffer. Thirty micrograms of protein per lane.
4870 Human Molecular Genetics, 2009, Vol. 18, No. 24cytoplasmic p62 (Supplementary Material, Fig. S1C). The data
indicate that TDP-43 is not involved in the neuropathology in
Fig4
2/2 mice.
Astrocytes exhibit high levels of p62
To identify the cells containing p62 in Fig4
2/2 brain, we
co-immunostained brain sections for p62 and cell-speciﬁc
markers. Extensive overlap was observed when cortical sec-
tions were stained for p62 and the astrocyte marker GFAP
(glial ﬁbrillary acidic protein) (Fig. 4A). In wild-type brain,
the levels of p62 and GFAP were low and no overlap was
detected. In mutant cerebellum, immunostaining detected
high levels of p62 in Bergmann glia (Fig. 4B and Supplemen-
tary Material, Fig. S2). These cells reside at the border
between the molecular and granule cell layers of the cerebel-
lum and their projections extend to excitatory synapses of the
Purkinje cell dendritic arbor. Consistent with the intensity of
immunostaining, western blotting demonstrated signiﬁcant
accumulation of both full-length and degraded GFAP
(Fig. 4C).
To investigate the temporal relationship between spongiform
degeneration and the appearance of p62-containing astrocytes,
we examined Fig4
2/2 brain at 1 week of age, when a small
Figure 4. Accumulation of p62 in reactive astrocytes and neurons of Fig4
2/2 brain. (A) Immunostaining of cortical sections demonstrates co-localization of p62
and GFAP, an astrocyte marker. (B) p62 accumulation in GFAP-positive Bergmann glia in mutant cerebellum; see also Supplementary Material, Fig. S2.
(C) Western blot demonstrates increased abundance of full-length GFAP and degradation products in mutant brain; 30 mg protein per lane. (D) Lack of p62
accumulation in astrocytes in the CA1 region of the hippocampus from Fig4
þ/þ epileptic brain. (E) Neurons were identiﬁed with antibody to the nuclear
marker NeuN. Only a small number of NeuN-labeled nuclei are associated with cytoplasmic p62 (insert, arrowheads). (F) Most of the p62 in this section is
localized in GFAP-positive astrocytes, as also seen in (A).
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but not in cortex (3). Co-staining of p62 and GFAP was evident
in the thalamus, but not in the cortex (Fig. 5 and Supplementary
Material, Fig. S3). p62-positive astrocytes were also present in
the axonal tracts near the cerebellar nuclei (Fig.5),a region that
is severely affected at later stages (3) (Supplementary Material,
Fig. S3). Thus, the appearance of p62-positive astrocytes
accompanies the earliest signs of neurodegeneration, consistent
with a primary role in pathogenesis.
As a control for the speciﬁcity of p62 accumulation in
Fig4
2/2 astrocytes, we examined Fig4
þ/þ astrocytes in Q54
mice, a model of temporal lobe epilepsy with hippocampal
sclerosis (19). Intensely staining GFAP-positive astrocytes
are present in the CA1 region of Q54 hippocampus, but
these astrocytes do not contain high levels of p62 (Fig. 4D).
Thus, p62 accumulation is not a general feature of astrocyto-
sis, but is speciﬁc to Fig4
2/2 brain.
p62 in neurons and other types of glia
To assess the accumulation of p62 in neurons, brain slices
were co-stained for p62 and NeuN, a marker of neuronal
nuclei. A small number of neurons contain cytoplasmic p62
surrounding the NeuN-positive nucleus (Fig. 4E, insert).
However, the major portion of p62 staining is in astrocytes
(Fig. 4F), as also discussed above.
Oligodendrocytes were identiﬁed by in situ hybridization
with a cDNA probe for MAG (myelin-associated glyco-
protein). MAG-positive cells did not contain p62 (Supplemen-
tary Material, Fig. S4B). Microglia were identiﬁed by
immunostaining with the marker Iba1. Numerous microglia
were present in mutant brain, suggestive of activation by
ongoing neuronal damage (Supplementary Material,
Fig. S4B). However, there was no overlap of immunostaining
for Iba1 and p62. Thus, the major site of p62 accumulation is
in astrocytes, with a small contribution from neurons.
Co-localization of LAMP-2 and p62 in astrocytes
LAMP-2isahighlyglycosylatedmembraneproteinthatisloca-
lized to vesicles of the late endosome and lysosome (20). We
previously demonstrated the presence of LAMP-2 in the limit-
ing membrane of the cytoplasmic vacuoles in cultured ﬁbro-
blasts from Fig4
2/2 mice (3). Western blot analysis of total
brain homogenate revealed signiﬁcant elevation of LAMP-2
in mutant brain (Fig. 6A). The abundance of LAMP-2 in
10 mg of mutant brain is comparable with that in 30 mg of wild-
type brain (Fig. 6A). The elevation of LAMP-2 is thus 3-fold,
similar to the elevation of p62 (Fig. 1A).
To determine which cells accumulate LAMP-2, we
co-stained cortical sections for LAMP-2 and cell-speciﬁc
markers. The majority of LAMP-2 staining was localized to
GFAP-positive astrocytes (Fig. 6B). LAMP-2 is thus accumu-
lating in the same cells that accumulate p62 and ubiquinated
protein (Figs 3 and 6). High magniﬁcation confocal imaging
demonstrated co-localization of p62 and LAMP-2 in intra-
cellular vesicles (Fig. 6D).
LAMP-2 positive vesicles in cultured Fig4
2/2 neurons
We previously described neuronal vacuolization in sensory
ganglia, thalamus, brain stem and ventral spinal cord of
Fig4
2/2 brain (3). Because only a few vacuolized neurons
are visible in brain sections, we examined LAMP-2 staining
of neuronal vacuoles using cultured neurons. Cerebellar
granule cells were isolated from Fig4
2/2 mice at postnatal
day 3 and cultured for 11 days as described (21). Approxi-
mately 25% of the cultured neurons exhibit extensive vacuoli-
zation with LAMP-2 staining of vacuoles. In the most severely
affected neurons, vacuoles ﬁlled the soma and neuronal
processes (Fig. 6E). The dramatic appearance of these cells
suggests that the ﬁrst step in pathogenesis may be neuronal
cell death due to extensive vacuolization, followed sequen-
tially by a defective astrocyte response and spongiform
degeneration.
Abnormal autophagy in Vac14 mice mutant
VAC14 is a component of the PI(3,5)P2 regulatory complex
that acts as a scaffold protein and binds directly to FIG4 and
the kinase FAB1 (Fig. 7A). The Vac14
L156R mutation in the
mouse mutant ingls disrupts the interaction with FAB1, result-
ing in reduced PI(3,5)P2 and neurodegeneration that mimic the
Fig4
2/2 phenotype (2). We therefore examined the ingls
mouse as an independent test of the hypothesis that reduced
PI(3,5)P2 leads to abnormal autophagy.
Examination of brain homogenates by western blotting
demonstrated elevated levels of both p62 and LC3-II in ingls
brain (Fig. 7B). The p62 is co-localized with ubiquitin in
brain sections from the ingls mouse (Fig. 7C). Numerous acti-
Figure 5. p62-containing astrocytes in Fig4
2/2 brain at 1 week of age. (A) Accumulation of p62 in GFAP-positive astrocytes in the thalamus, which exhibits
spongiform degeneration at 1 week of age (3). (B) Accumulation of p62 in white matter tracts around the cerebellar nuclei, a site of extensive spongiform
degeneration in older animals. (C) The cortex is unaffected at P7 (3).
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ing (Fig. 7D). A small proportion of neurons in the ingls brain
was positive for p62 (Fig. 7D, insert, arrowheads). LAMP-2 is
also elevated in ingls brain (Fig. 7E). Overall, the accumulation
and cellular location of autophagy markers in the ingls mutant
closely resembles those of Fig4
2/2 mice, supporting the view
that the deﬁciency of PI(3,5)P2 is responsible for defective
autophagy and neurodegeneration in both mutants.
DISCUSSION
Autophagy and PI(3,5)P2
Inyeast,mutationsofthePI(3,5)P2regulatorycomplexresultin
enlargement of the vacuole organelle, but do not interfere with
autophagy (10).However, inDrosophilaand inCaenorhabditis
elegans, mutation of the FAB1 component of the regulatory
complex led to accumulation of the LC3 homologs (22,23),
Figure 6. Accumulation of LAMP-2 in Fig4
2/2 brain. LAMP-2 is a major component of lysosomal membranes, and is also present in late endosomes and
autophagosomes. (A) Western blot demonstrates accumulation of LAMP-2 in mutant brain (left panel) with quantitative comparison (right panel). (B)
LAMP-2 is concentrated in GFAP-positive astrocytes and not in NeuN-poistive neurons. (C) Co-localization of LAMP-2 and p62. (D) High-resolution confocal
imaging ( 180) demonstrates subcellular co-localization of LAMP-2 and p62. (E) In cultured cerebellar granule neurons from Fig4
2/2 mice, soma and pro-
cesses (insert) are ﬁlled with LAMP-2-positive vacuoles.
Human Molecular Genetics, 2009, Vol. 18, No. 24 4873indicating that this pathway has diverged between yeast and
higher organisms. The present report is directed toward the
role of PI(3,5)P2 signaling in mammalian autophagy in vivo.
In two independent mouse mutants deﬁcient in PI(3,5)P2, elev-
ated levels of the autophagy markers LC3-II and p62, were
detected in brain. Induction of autophagic ﬂux is often
accompanied by elevation of LC3-II levels and reduced levels
ofp62(24).Inmutantbrain,thelevelofp62isgreatlyincreased
andseveralproteins involvedinregulation ofautophagy are not
altered. These observations indicate that the predominant effect
of deﬁcient PI(3,5)P2 is to block the progression of autophagy.
This view is supported by the recent observation that inhibition
ofFAB1inculturedcellsresultsinaccumulationofLC3-II(25).
Our data do not rule out the possibility that there may also be
some mTOR-independent induction of basal autophagy.
The accumulated p62 in mutant brain is located in insoluble
inclusion bodies that also contain ubiquitinated protein.
Inclusion bodies containing p62 and ubiquitin are character-
istic of several types of neurodegenerative disease (26). It is
clear that nervous system is particularly susceptible to
reduction of PI(3,5)P2 in vivo, since other tissues do not
exhibit cellular vacuolization or accumulation of autophagy
intermediates.
Two models for the speciﬁc role of PI(3,5)P2 in autophagy
may be considered (Fig. 8). In the ﬁrst model, PI(3,5)P2 is
located on the membranes of autophagosomes, late endosomes
and/or lysosomes, where it serves as a molecular signal for
vesicle fusion leading to mature autolysosomes. Deﬁciency
of PI(3,5)P2 on these membranes could slow or prevent
vesicle fusion events (Fig. 8-1), leading to accumulation of
vesicles containing p62. An alternate model is that PI(3,5)P2
is required for recycling of the autolysosome membrane
after fusion of the amphisome with the lysosome (Fig. 8-2).
In this model, autophagy intermediates could accumulate
due to the deﬁciency of membrane components required for
continued generation and maturation of autophagosomes.
The second model is comparable with the effect of PI(3,5)P2
deﬁciency in yeast, where the enlarged vacuole appears to
result from failure of vacuole ﬁssion and budding (10). The
second model is supported by the co-localization of p62
with LAMP-2, which implies that vesicle fusion has occurred.
The two alternative models are not mutually exclusive, and
both steps may be impaired in PI(3,5)P2-deﬁcient mice. The
progression of autophagy in the mutant mice may be only par-
Figure 7. Impaired autophagy and astrocytosis in a second mouse mutant affecting PI(3,5)P2.( A) The protein VAC14 binds FIG4 and FAB1 kinase in the mol-
ecular complex that regulates PI(3,5)P2 synthesis. The Vac14-L156R mutation (red) in the ingls mutant mouse results in destabilization of the complex and
reduced levels of PI(3,5)P2 (2). (B) Elevated levels of p62 and LC3-II in brain homogenates from Vac14-mutant mice. Each lane contains 30 mg of protein.
(C) Co-localization of p62 and ubiquitin in ingls cortex. (D) Accumulation of p62 in astrocytes and neurons. (E) Accumulation of LAMP-2 in ingls brain;
30 mg protein per lane.
Figure 8. Schematic depiction of maturation and resolution of the autophago-
some. (A) Proteins that accumulate in brain of pale tremor (Fig4) and ingls
(Vac14) mutant mice. (B) Model of maturation of autophagic vesicles, with
two potential sites of slowdown or blockage that could explain the accumu-
lation of autophagosome and lysosome marker proteins.
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PI(3,5)P2 and many tissues, including liver, do not exhibit
degeneration (2). Deﬁnitive understanding of the role of
PI(3,5)P2 in this pathway will require more detailed infor-
mation regarding the precise localization of PI(3,5)P2 and its
regulatory complex in mammalian cells.
Roles of neurons and astrocytes
Accumulation of membrane-bounded vesicles in neurons of
the CNS and peripheral nervous system was found to be an
early feature of neurodegeneration in Fig4 and Vac14
mutant mice (2,3). The current work demonstrates that the
majority of accumulated p62 in mutant brain is located
within astrocytes. Astrocytes comprise a majority of cells in
the CNS, and regulate reuptake of glutamate from excitatory
synapses and response to neuronal injury (27). Abnormal
astrocytes are present as early as 1 week of age, speciﬁcally
in brain regions that later exhibit the greatest degeneration.
Thus, both neurons and astrocytes are affected early in
disease progression, and conditional inactivation will be
required to separate their contributions. The data are consist-
ent with a model of pathogenesis in which the initiating event
is vesicle accumulation and death of neurons, followed by
recruitment of astroctyes which are unable to respond ade-
quately to the injury, leading to local neurotoxicity and gen-
eration of the empty spaces characteristic of spongiform
degeneration. This model is supported by the dramatic
accumulation of LAMP-2-positive vacuoles in soma and pro-
cesses of neurons in culture. The small number of
p62-positive neurons visible in brain sections may reﬂect
the short survival time of neurons after the start of vacuoliza-
tion. The vulnerability of neurons may be related to their
postmitotic state, since accumulated vesicles are not diluted
by distribution to daughter cells during cell division. The
high level of membrane turnover in neurons is thought to
contribute to the unique dependence of neurons on autop-
hagy.
Astrocytes and Bergmann glia in the Fig4 and Vac14
mutant brains exhibit morphological features of activation
such as hypertrophy, elongated processes, and high GFAP
content. The detection of increased GFAP on western blots
of whole brain homogenates demonstrates the high level of
astrocytosis in the degenerating brains. p62 accumulates in
astrocytes of Fig4 or Vac14 mutant mice, but not in a model
of seizure-induced astrocytosis.
The relative contribution of neurons and astrocytes to the
development of ALS has been evaluated in the mouse model
of SOD1-dependent ALS. Both FIG4 and SOD1 are ubiqui-
tously expressed ‘housekeeping genes’ in which certain mis-
sense mutations result in late-onset neurodegenerative
disease. p62/ubiquitin inclusion bodies are observed in both
neurons and astrocytes of mice carrying ALS-associated
mutations of SOD1. Global expression of mutant SOD1 trans-
genes in the mouse recapitulates the human disease, but tissue-
speciﬁc transgene expression in astrocytes does not itself
induce disease (28). Tissue-speciﬁc expression in neurons is
pathogenic if expression is sufﬁciently high (29,30). Using
conditional knock-out technology, tissue-speciﬁc knock-out
of mutant SOD1 expression in astrocytes was shown to
delay disease progression (31). Recapitulation of the SOD1
mutant phenotype requires interaction between neurons, astro-
cytes, microglia and, possibly, other cell types. In Fig4
2/2
mice, affected cells include neurons, astrocytes, and
Schwann cells (3,9). Future application of the conditional
knock-out approach will permit dissection of the contributions
of these and other cell types to PI(3,5)P2-deﬁcient neuro-
pathology.
Autophagy and neurological disease
The combination of p62/ubiquitin-positive inclusion bodies
and neurodegeneration may result from three distinct cat-
egories of gene mutations. The most extensively studied are
dominantly inherited mutations in substrates of autophagy
that produce ‘toxic’ proteins that accumulate because they
are resistant to degradation. Examples include LRRK2 and
PARKIN in Parkinson’s disease, SOD1 and TDP-43 in ALS,
and the expanded polyglutamine repeat-containing huntingtin
protein. In these cases, the mutant protein is a major com-
ponent of the inclusion bodies, and accumulation of the
mutant protein is the cause of degeneration.
The lysosomal diseases represent a second category of neu-
rodegeneration with p62/ubiquitin inclusion bodies. In these
disorders, mutation of a lysosomal enzyme or ion-channel
interferes with protein degradation, resulting in back-up
accumulation of autophagy intermediates (32). Up-regulation
of the autophagy pathway is observed in these disorders,
apparently as an attempt to compensate for the accumulation
of non-degraded proteins.
We propose that mutations that directly affect components
of the autophagy machinery may be considered a third cat-
egory of inclusion-body-related neurodegenerative disease,
and that the Fig4 and Vac14 mutations affecting PI(3,5)P2
fall into this category. Accumulation within neurons of pro-
teins that are normally degraded by autophagy is likely to
mediate neuronal cell death. Neuron-speciﬁc inactivation of
the autophagy proteins ATG5 and ATG7 generates a pattern
of neurodegeneration and accumulation of p62/ubiquitin
inclusion bodies very similar to those described here (33,34).
Other neurodegenerative disorders that may directly affect
autophagy are Chorea acanthocytosis due to mutation of the
endosomal protein Soi3 (VPS13a), which interacts with
FAB1 (35,36), and ALS with Frontotemporal Dementia due
to mutation of the CHMP2B subunit of the ESCRT complex
(37,38).
p62/ubiquitin inclusion bodies are a hallmark of ALS.
Detection of p62/ubiquitin inclusions in Fig4-deﬁcient mice
supports our recent report that heterozygosity for partial or
complete loss-of-function alleles of FIG4 may be a risk
factor for ALS (4). The importance of autophagy in
ALS pathogenesis is also supported by recent evidence that
increasing autophagy via XBP-1 deﬁciency protects against
SOD1-induced ALS in the mouse (39).
The current work suggests that defective autophagy is a
potential target for treatment of patients with mutations in
FIG4. Induction of autophagy is also protective against the
toxicity of mutant huntingtin in cultured neurons and in vivo
(40,41). Long-term in vivo treatment with rapamycin,
another inducer of autophagy, is well tolerated in the mouse
Human Molecular Genetics, 2009, Vol. 18, No. 24 4875and leads to extended lifespan (42). Drugs that increase the
abundance of PI3K may induce autophagy in part by increas-
ing the substrate for conversion of PI3P to PI(3,5)P2.I n
addition to suggesting therapeutic approaches, our obser-
vations indicate that other genes encoding components of
the autophagy machinery should be evaluated for their role
in inherited neurodegenerative disorders.
MATERIALS AND METHODS
Animals
The pale tremor mutant, Fig4
2/2, is derived from a spon-
taneous mutant that arose on a mixed inbred background (3).
Fig4
2/2 mice are maintained as a recombinant inbred strain
that was derived from an F2 cross with strain CAST/EiJ.
The line is maintained by brother   sister mating of heterozy-
gous carriers, and is now at generation N10. The ingls mutant
(infantile gliosis) carrying the Vac14
L156R mutation arose on
strain DBA/2J and is maintained as a congenic line on strain
C57BL/6J (2). The congenic line B6.D2-Vac14
ingls/J (N23)
was obtained from the Jackson Laboratory (stock number
003095). Experiments were carried out on Fig4
2/2 mice
between 3 and 4 weeks of age, unless otherwise indicated,
and ingls mice at 2 weeks of age. The Q54 mice with temporal
lobe epilepsy due to a mutation in sodium channel Scn2a are
maintained on the C57BL/6J background (N15) (19). Frozen
brain from affected Q54 (B6.Q54XSJL/J)F1 mice was pro-
vided by Jennifer Kearney (Vanderbilt University). Animals
were housed and cared for in accordance with NIH guidelines,
and experiments were approved by the University of Michigan
Committee on Use and Care of Animals.
Western blot analysis
Tissue homogenates (10%, weight/volume) were prepared by
homogenization with a Polytron homogenizer in radioimmu-
noprecipitation (RIPA) buffer (150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS in 25 mM Tris, pH 7.5) con-
taining complete EDTA-free protease inhibitor cocktail
(Roche) and 1:1000 b-mercaptoethanol. Homogenates were
centrifuged at 15 000g. Protein concentration was determined
in triplicate using the bicinchoninic acid protein assay reagent
(Pierce Chem.) Pellets were resuspended in RIPA buffer using
the Polytron homogenizer. Samples were boiled for 3 min in
the presence of b-mercaptoethanol prior to electrophoresis
on precast 4–20% SDS-PAGE gels (Criterion) and transfer
to Hybond nitrocellulose membranes (Amersham Bio-
sciences). Membranes were pre-incubated for 1 h at room
temperature in western blocking solution, 1% BSA fraction
V (Fischer Scientiﬁc) with 5% powdered milk (Amresco) in
TBST (Tris-buffered saline with Tween 20). Primary antibody
incubation was carried out overnight at 48C. Guinea pig
anti-p62 (American Research Products) was used at 1:1000,
rabbit anti-LC3 (Novus Biologicals) at 1:500, anti-TDP-43
(Proteintech Group) at 1:500, rat anti-LAMP2 (ABL-93 con-
centrate fraction, Iowa Hybridoma bank) at 1:1000, rabbit
anti-GFAP (Abcam) at 1:1000, rabbit anti-Beclin-1 (Santa
Cruz) at 1:1000 and rabbit anti-mTOR (Cell Signaling) at
1:1000. Membranes were blocked in 3% BSA prior to staining
with mouse anti-GAPDH (1:30,000, Abcam), rabbit anti
phospho-p70S6 kinase (1:250, Cell Signaling) and rabbit
phospho-mTOR Ser2448 (1:1000, Cell Signaling). Mem-
branes were washed in TBST and incubated with peroxidase-
labeled secondary antibodies for 1 h at room temperature.
Chemiluminescence was detected with the Supersignal West
Femto chemiluminescence reagent (Pierce) and Hybond-CL
autoradiography ﬁlm (Denville Scientiﬁc).
Quantitation of p62/SQSTM1 mRNA
RNA was extracted from whole brain (n ¼ 3 for each geno-
type) using the TriZol reagent (Invitrogen). cDNA was gener-
ated using oligo-dT primers with the SuperScript ﬁrst-strand
synthesis RT-PCR kit (Invitrogen). Expression was measured
using predesigned TaqMan assay probes (www.
appliedbiosystems.com) with analysis on a StepOne Plus real-
time PCR system (ABI). Each sample was assayed in quadru-
plicate and expression of p62/SQSTM1 was normalized to the
Tata binding protein (Tbp).
Immunocytochemistry
Fresh frozen saggital cryosections (10 mm) were dried at room
temp for 20 min, ﬁxed in fresh 3.2% paraformaldehyde
(Pierce) for 20 min, permeabilized with 0.2% Triton X-100
and blocked in 10% goat serum. Primary antibody to p62
(1:200 mouse anti-p62, Abnova H00008878-M01) or ubiquitin
(or 1:200 rabbit anti-ubiquitin, DAKO) was applied and sec-
tions were incubated overnight at 48C in 5% goat serum.
Peroxidase-diaminobenzidine staining was carried out with
the Histostain kit (Zymed). Brightﬁeld images were captured
on an Olympus BX51 microscope equipped with Olympus
DP-70 digital camera.
Immunoﬂuorescence
Brain sections were prepared as above. The concentration of
primary antibodies was 1:200 mouse anti-p62 (Abnova),
1:500 rabbit anti-GFAP (Abcam), 1:100 rabbit anti-TDP-43
(Proteintech Group), 1:250 rabbit anti-Iba1 (Wako Pure
Chemical Industries), 1:200 rabbit anti-ubiquitin (Dako) and
1:5000 rat anti-LAMP-2 (ABL-93 concentrate). Prior to stain-
ing with anti-Iba1 and anti-LAMP-2, sections were treated
with 0.2% Saponin (Sigma). Secondary detection was
carried out with antibodies conjugated to Alexa 488 or
Alexa 594 (Invitrogen) at dilutions of 1:500 to 1:1000. For
immunoﬂuorescence in the blue range, rabbit primary
antibodies were detected with 1:500 biotin-conjugated goat
anti-rabbit (Invitrogen) and 1:500 Neutravidin Alexa 350
(Invitrogen). Mouse monoclonal anti-NeuN conjugated to
Alexa 488 (Millipore) was applied to sections at 1:100 after
secondary detection of mouse anti-p62. Images were captured
on an Olympus BX51 microscope equipped with epiﬂuores-
cence and an Olympus DP-70 digital camera. Images were
processed and merged using Adobe Photoshop software. A
Zeiss LSM 510-META laser scanning confocal microscope
was used for imaging Fig. 6D and E.
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Mice were perfused with 2.5% glutaraldehyde, and tissue
was processed for electron microscopy as described
previously (43).
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